REG - BiVictriX Therapcts. - Appointment of Alex Hughes as CFO

Bivictrix TherapeuticsAnnouncement

01/03/2023 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230301:nRSA4157Ra&default-theme=true

RNS Number : 4157R  BiVictriX Therapeutics PLC  01 March 2023

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

 

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or the "Company")

 

 

Appointment of Alex Hughes as Chief Financial Officer

 

Alderley Park, 1(st) March 2023 - BiVictriX Therapeutics plc (AIM: BVX), an
emerging biotechnology company applying a novel approach to develop
next-generation cancer therapies with improved tolerability and anti-cancer
activity, today announces that it has appointed Alex Hughes as Chief Financial
Officer. Glyn Baker will be stepping down from the position on 31(st) March.

 

Alex has held senior finance and operational positions in listed global
companies for 10 years, developing and implementing strong control
environments whilst working with leadership teams to achieve strategic company
goals.  Most recently, Alex has contributed to the growth of a US listed
biotechnology company, Instil Bio Inc., as finance director. Previously, he
held roles at Argent Energy and Luxfer MEL Technologies.

 

Tiffany Thorn, Chief Executive of BiVictriX, commented: "We look forward to
working with Alex as we enter this new period of growth following our recent
positive preclinical safety results of BVX001. I am confident that his
extensive financial experience will help guide the Company, as we continue to
make great progress in the development of our urgently-needed next-generation
therapeutics. I would personally like to thank Glyn for his dedication and
much valued support during his time with us."

 

Alex Hughes, BiVictriX's incoming Chief Financial Officer, added: "I am
delighted to be joining the BiVictrix team.  I believe the Company's
potential to develop next generation cancer therapies for patients is
tremendous and I look forward to being part of such a talented and passionate
team.  Having previously supported similar leadership teams, I am confident
that we can continue our growth and achieve our objectives."

 

   For more information, please contact:

BiVictriX Therapeutics plc
 Tiffany Thorn, Chief Executive Officer

 Michael Kauffman, Non-Executive Chairman             Email: info@bivictrix.com (mailto:info@bivictrix.com)

 SP Angel Corporate Finance LLP (NOMAD and Broker)    Tel: +44 (0) 20 3470 0470
 David Hignell, Kasia Brzozowska (Corporate Finance)

 Vadim Alexandre, Rob Rees (Sales and Broking)

 Panmure Gordon (UK) Limited (Joint Broker)           Tel: +44 (0) 20 7886 2500
 Rupert Dearden/Freddy Crossley/Emma Earl

 Consilium Strategic Communications
 Mary-Jane Elliott, Namrata Taak,                     Tel: +44 (0) 20 3709 5700

 Genevieve Wilson, Alex Gunter                        Email: Bivictrix@consilium-comms.com (mailto:Bivictrix@consilium-comms.com)

 

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is
focused on leveraging clinical experience to develop a new class of highly
selective, next generation cancer therapeutics which exhibit superior potency,
whilst significantly reducing treatment-related toxicities.

 

The Company utilises a first-in-class approach to generate a proprietary
pipeline of Bi-Cygni® Antibody Drug Conjugate therapeutics which are designed
to selectively target cancer-specific antigen pairs, or "Bi-Cygni®
fingerprints", on tumour cells, which are largely absent from healthy cells.

 

BiVictriX has established a growing proprietary library of cancer-specific
Bi-Cygni® fingerprints, which enable the Company to target a diverse array of
different cancer types. The Company utilises these novel Bi-Cygni®
fingerprints, together with the Company's novel Antibody Drug Conjugate
therapeutic design, to develop more effective and safer therapeutics to target
cancers that are expected to constitute orphan indications and areas of high
unmet medical need.

 

Find out more about BiVictriX online at www.bivictrix.com
(http://www.bivictrix.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSEEFUAEDSELE